Published : 16 Jan 2012
A Oregon drug development company, with innovative technology licensed from Portland State University, is developing 3 projects pipeline two antimalarial drugs and one antibacterial. Today they have retained Aagami to partner with Indian Pharmaceutical companies.
The company has a novel approach, modifying a drug that has lost effectiveness due to drug-resistance by covalently bonding it to a molecule that overcomes the resistance. This results in new patentable drugs that are potent in animals, safe and cost effective.
They have understood the strength of Indian Pharmaceuticals companies for their development capabilities whether CMC or Clinical and also appreciate their market reach in the regions most afflicted by Malaria. So to provide further impetus to their projects and move quickly to market the company is seeking Indian pharmaceutical partner for licensing or co-development of the first drug product.
Aagami in its qualifying research have found that there are at least half a dozen large Indian companies with extensive portfolio of such Anti-Malarial drugs. In fact some of them supply majority of global needs of particular molecules.